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BST2 (bonemarrowstromal antigen 2)/tetherin is a re-
striction factor of enveloped viruses, which blocks the
release of viral particles. HIV-1 encodes proteins that
antagonize this innate barrier, including the acces-
sory protein Vpu. Here, we investigate whether the
autophagy pathway and/or ATG proteins are hijacked
by HIV-1 Vpu to circumvent BST2 restriction of viral
release. We report that BST2 and Vpu are present in
LC3-positive compartments. We found that Vpu
selectively interacts with the ATG8 ortholog LC3C
through the Vpu L63VEM66 sequence. This sequence
is required for Vpu to antagonize BST2 restriction.
LC3C expression favors the removal of BST2 from
the HIV-1 budding site, and thus HIV-1 release in
BST2-expressing cells. Additionally, ATG5 and beclin
1/ATG6, but not all the components of the autophagy
pathway, act with LC3C to facilitate Vpu antagonism
of BST2 restriction. Altogether, our data support the
view that a non-canonical autophagy pathway remi-
niscent of LC3-associated phagocytosis contributes
to Vpu counteraction of BST2 restriction.
INTRODUCTION
Restriction factors are a set of proteins with direct antiviral ac-
tivity that constitute intrinsic cellular defenses against viral
infection (Malim and Bieniasz, 2012). Among them, BST2
(bone marrow stromal antigen 2)/tetherin considerably reduces
the release of enveloped viruses by physically trapping de novo
formedmature viral particles at the surface of infected cells (Neil
et al., 2008; Van Damme et al., 2008). The antiviral activity of
BST2 relies on its presence at the viral budding site and on its
ability to be incorporated into nascent budding virions, bridging
virions and cellular membranes. Lentiviruses have adopted
diverse strategies to antagonize this restriction and furtherCell Repor
This is an open access article under the CC BY-Noptimize viral release, notably by encoding viral proteins able
to interact with BST2 (Jia et al., 2009; Le Tortorec and Neil,
2009; Neil et al., 2008; Sauter et al., 2009; Van Damme et al.,
2008).
The HIV-1 Vpu protein promotes viral release by displacing
BST2 from viral budding sites and by downregulating cell sur-
face expression of BST2, with a variable magnitude, depending
on the cell type (Miyagi et al., 2009; Neil et al., 2008; Van
Damme et al., 2008). Both activities depend on a direct interac-
tion between the transmembrane domain of Vpu and that of
BST2 (McNatt et al., 2013; Vigan and Neil, 2010). Vpu downre-
gulates cell surface BST2 by perturbing its intracellular traf-
ficking. Notably, Vpu accelerates endosomal sorting com-
plexes required for transport (ESCRT)-mediated sorting of
BST2 to lysosomes and decreases the recycling of BST2 to
the plasma membrane (PM) by increasing the affinity of BST2
for Hrs (hepatocyte growth factor-regulated tyrosine kinase
substrate), an ESCRT-0 protein linking ubiquitinated cargos
to the ESCRT pathway (Dube´ et al., 2010; Janvier et al.,
2011; Mitchell et al., 2009). The molecular mechanism by which
Vpu removes BST2 from the budding site is not well under-
stood. Vpu-induced removal of BST2 from the viral budding
site is crucial to overcome BST2 restriction on HIV-1 release
and can be manifested without affecting the overall level of
BST2 at the cell surface (Jafari et al., 2014; McNatt et al.,
2013). Interestingly, several reports indicate that the ‘‘dileu-
cine’’-like motif E59VSAL63V64 present in the cytoplasmic tail
of Vpu is essential for Vpu activity on HIV-1 release (Jia
et al., 2014; Kueck and Neil, 2012; McNatt et al., 2013) and,
to a lesser extent, the two serine residues of the Vpu DS52-
GxxS56 motif previously involved in the recruitment of the
SCFß-TrCP complex for Vpu-induced proteasomal degradation
of CD4 (Mangeat et al., 2009; Margottin et al., 1998; Mitchell
et al., 2009). However, the requirement of bTrCP in Vpu antag-
onism of BST2 antiviral activity remains controversial and the
clathrin adaptor protein complex 1 (AP1), shown to interact
with the Vpu ‘‘dileucine’’-like motif, is dispensable for Vpu to
overcome BST2 restriction on HIV-1 release, suggesting that
Vpu subverts additional cellular machineries to counteractts 17, 2221–2233, November 22, 2016 ª 2016 The Author(s). 2221
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
BST2 restriction (Jia et al., 2014; Kueck and Neil, 2012; Tervo
et al., 2011).
Macroautophagy, referred herein as autophagy, is a highly
conserved degradative pathway that maintains cellular homeo-
stasis, responds to pathological processes, and combats in-
fections (Randow and M€unz, 2012). Autophagy requires the
hierarchical intervention of about 30 autophagy-related (ATG)
proteins, which regulate different stages of the process leading
to the sequestration of cargos in a double-membrane vacuole
called an autophagosome and their degradation after the fusion
of the autophagosomes with lysosomes (Mizushima et al., 2011).
Autophagy initiation depends on the ULK (Unc-51-like kinase)
complex, and nucleation involves the beclin 1-phosphatidylino-
sitol 3-kinase class III (PIK3C3)-ATG14 complex and the WIPI
(WD repeat domain phosphoinositide-interacting) proteins.
Elongation and closure of the autophagosome require two ubiq-
uitin (Ub)-like conjugation systems, which are distinct but inter-
connected, whereas RAB7A and Hrs regulate maturation of the
autophagosomes to autolysosomes (Mizushima et al., 2011).
The covalent conjugation of the Ub-like modifiers ATG12 and
LC3 (microtubule-associated protein light-chain; ATG8 in yeast)
to their substrates is mediated by specific ATG proteins.
Notably, the activity of the ATG5-ATG12:ATG16L multimeric
complex results in the lipidation of unconjugated LC3 (referred
as LC3-I) to phosphatidylethanolamine-conjugated LC3, named
LC3-II, which is the LC3 form tightly bound to autophagosomal
membranes (Mizushima et al., 2011). Importantly, the LC3/
ATG8 orthologs in humans, which encompass LC3 (LC3A,
LC3B, and LC3C) and the g-aminobutyric acid receptor-associ-
ated protein (GABARAP) (GABARAP, GABARAPL1, and GA-
BARAPL2) subfamilies, are also critical factors in cargo seq-
uestration during selective autophagy. Cargo recognition and
targeting is mediated via autophagy receptors that simulta-
neously recognize cargos tagged with degradation signals and
the autophagosomal membrane through their LC3-interacting
regions (LIRs) (Rogov et al., 2014).
Growing evidence demonstrates that the Ub-like autophagy
proteinsandsomecomponentsof theautophagymachineryaddi-
tionally regulatenon-autophagy-relatedcell functions, suchascell
homeostasis and resistance to pathogens (Codogno et al., 2011).
Notably, some ATG proteins are involved in LC3-associated
phagocytosis (LAP), a ULK-independent process, in which com-
ponents of the ATG machinery (such as ATG5, beclin 1, and
LC3)directlymodify thesinglemembraneofphagosomestoassist
and accelerate the degradation of phagocytosed elements from
the plasma membrane (Florey et al., 2011; Martinez et al., 2015;
Sanjuan et al., 2007).
Pathogens have evolved strategies to escape autophagy or to
actively subvert its components to promote their own replication
(Deretic, 2010). Here, we examined whether ATG proteins are
usurped by HIV-1 Vpu to circumvent BST2 restriction on viral
dissemination. Interestingly, we highlighted that ATG5 and beclin
1, but not all the components of the autophagic pathway, act
with LC3C to facilitate Vpu-mediated antagonism of BST2 re-
striction. We revealed a selective interaction between HIV-1
Vpu and LC3C. Finally, we showed that LC3C contributes to
Vpu-induced removal of BST2 from the HIV-1 budding site to
favor efficient HIV-1 release.2222 Cell Reports 17, 2221–2233, November 22, 2016RESULTS
Some ATG Proteins, but Not All Components of the
Autophagy Pathway, Are Required for Efficient HIV-1
Release
To investigate whether the autophagy pathway was required for
Vpu to counteract BST2 and favor HIV-1 release, we depleted
essential ATG proteins and analyzed HIV-1 release in restrictive
HeLa cells that express the restriction factor BST2. Among the
ATG proteins, we knockdowned ULK1 and FIP200, which con-
trol the initiation step, beclin 1 and ATG14, two components of
the PIK3C3-ATG14 complex that regulates the nucleation step,
and ATG5, a key protein implicated in the autophagosome
expansion and closure steps. HeLa cells were treated with cor-
responding small interfering RNAs (siRNAs) and infected with
wild-type (WT) HIV-1 NL4-3 pseudotyped with VSV-G, enabling
us to monitor HIV-1 production after a single round of infection.
SiRNA knockdown of ULK1, FIP200, ATG14, beclin 1, and ATG5
was verified by western blotting (Figures S1A–S1E) or by qRT-
PCR (Figure S1F). HIV-1 release was then assessed by ELISA
quantification of the viral CAp24 (Capsid) protein, which is
derived from the structural Gag precursor, present in the pro-
ducer cells and in the cell supernatants. Calculation of the
HIV-1 release index, corresponding to the ratio of released
CAp24 to total CAp24 present (released CAp24 + cell-associ-
ated CAp24) in cell culture revealed that depletion of FIP200,
ULK1, and ATG14 did not affect HIV-1 release compared to
the control cells (Figures 1A and S1G–S1J). By contrast, HIV-1
release was decreased following beclin 1 (30% decrease)
and ATG5 depletion (40% decrease) (Figures 1A and S1K). In
ATG5-knockdown cells, this effect was the result of an accumu-
lation of cell-associated HIV-1 CAp24 and a decrease of HIV-1
released in the supernatant (Figures 1B and 1C). Interestingly,
depletion of ATG5 and beclin 1 in HEK293T cells, which do not
normally express BST2, did not affect HIV-1 release (Figures
S1L–S1O). In contrast to what was observed in HeLa cells, the
reduced amount of CAp24 in pelleted virions was linked with a
decrease in the amount of cell-associated CAp24 in ATG5 and
beclin 1-silenced HEK293T cells (Figures S1M and S1O), sug-
gesting reduced permissiveness of siRNA-treated HEK293T
cells to HIV-1 infection or the requirement of these ATG proteins
for some other steps of the virus replication cycle. Thus, in
contrast to conventional autophagy, our data suggest that effi-
cient HIV-1 release in HeLa cells requires the contribution of
specific ATG proteins (ATG5 and beclin 1), but is independent
of the ATG14 protein or of the key components of the initiation
complex of autophagy ULK1 and FIP200.
LC3C Contributes to Efficient HIV-1 Release
Together with LC3 proteins, ATG5 and beclin 1 have previously
been implicated in LAP, a process independent of the initiation
complex of autophagy. We thus explored whether the human
LC3/ATG8 orthologs contribute to regulating HIV-1 release by
silencing the expression of LC3- and GABARAP-subfamily
members (LC3A, LC3B, LC3C, GABARAP, GABARAPL1, and
GABARAPL2) in HeLa cells. Efficiency of silencing of each hu-
man ATG8 ortholog was verified by western blotting of endoge-
nous or transfected forms of ATG8 orthologs (Figures S2A–S2F),
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Figure 1. Some ATG Proteins, but Not All Components of the Autophagy Pathway, Are Required for Efficient HIV-1 Release
(A) HeLa cells transfected with indicated siRNA were infected with a VSV-G pseudotyped WT NL4-3 HIV-1 at a MOI of 0.5. HIV-1-cell-associated CAp24 and
released CAp24 were measured by ELISA. HIV-1 release was calculated as the ratio between released CAp24 and total CAp24. Results were normalized to
control cells, which were set as 100%. Error bars represent SEM calculated on three independent experiments done in duplicate. **p < 0.01.
(B) Western blot analysis of HIV-1 Gag and CAp24 products in infected siRNA-treated cells (upper panels) and pelleted virus (lower panel). Actin is the loading
control. Equal volumes of the viral samples were loaded. This western blot is representative of three independent experiments.
(C) Cell-associated CAp24 and released CAp24 were measured by ELISA for siRNA-treated HeLa cells and normalized to control cells, which were set as 100%.
Error bars represent SEM calculated on three independent experiments done in duplicate. **p < 0.01.considering the inefficacy of commercial antibodies to detect
these ATG8 orthologs in crude HeLa cell lysates. We also
checked efficiency of LC3C depletion by qRT-PCR (Figure S2G)
and by western blotting after immunoprecipitation of endo-
genous LC3C (Figure S2H, lane 5 versus lane 4). LC3C silencing
resulted in a 30% decrease of HIV-1 release (Figure 2A)
compared to control cells, whereas depletion of other human
ATG8 orthologs did not affect release (Figures S2I and S2J).
Western blot analysis showed an accumulation of CAp24
and Pr55gag cleavage products upon LC3C depletion (Fig-
ure 2B). Consistent with this observation, ELISA quantification
of CAp24 yielded a 2-fold increase in cell-associated CAp24
(Figure 2C). This accumulation was associated with a decrease
of released virus (Figure 2B, lower panel), with 30% less
CAp24 detected in the supernatant compared to the control (Fig-
ure 2C). This decrease of released CAp24 correlated with a
5-fold decrease of the viral particle titer (Figures S3A–S3C).
Similar results were also obtained upon ATG5 and beclin 1
depletion (Figure S3C). To confirm the role of LC3C on HIV-1
release, we knocked out the LC3C gene in HeLa cells using
the clustered regularly interspaced short palindromic repeats
(CRISPR)-Cas9 system. HeLa clones lacking LC3C were
screened by PCR amplification of the targeted regions of the
genome and by western blot after immunoprecipitation of
endogenous LC3C (Figures S3D–S3F). LC3C/ clones (CRISPR
96#212 and 97#9) were transfected with WT HIV-1 NL4-3 pro-
viral DNA. As previously shown in siRNA interference experi-
ments, ELISA quantification of CAp24 yielded a decrease of
released virus, with 50% to 60% less CAp24 detected in
the supernatant, depending on the CRISPR clones used,
compared to the control (Figure 2D). This decrease is associated
with an accumulation of the CAp24 associated with producer
cells (Figures 2D–2F), leading to a decreased HIV-1 release
in LC3C/ clones. Altogether, these data indicate that LC3C
contributes to efficient HIV-1 production in HeLa cells.In contrast to classical autophagy, in which cargos are en-
wrapped by double membrane autophagosomes, LC3-associ-
ated phagocytosis favors the degradation of phagocytosed
elements from the plasmamembrane in single-membrane phag-
osomes decorated with the LC3-lipidated form (Martinez et al.,
2015). We thus examined by electron microscopy ultrathin
cryosections from infected LC3C-depleted cells immunolabeled
for HIV-1 CAp24 or MAp17 (Figure 2G). Interestingly, numerous
intracellular compartments containing mature virus labeled
with HIV-1 CAp24 and MAp17 antibodies were seen in LC3C-
depleted cells (panels b–d, white arrows). Only rare viruses
were bundled in intracellular structures in control cells, where
viruses were mainly observed at the cell surface (panel a, black
arrows). In cells depleted for LC3C, viruses appeared seques-
tered in single membrane-bound vesicles (magnified areas on
the right, panels b–d).
All together, these data show that LC3C depletion reduces
HIV-1 release in HeLa cells and induces the retention of mature
viruses in intracellular single membrane-bound vesicles.
Effect of LC3C on HIV-1 Release Requires BST2
Expression
We thus explored whether the effect of LC3C depletion on HIV-1
release was related to BST2 expression. HeLa cells were trans-
fected with control siRNA or siRNA targeting LC3C and BST2
either separately or together and then infected with WT or
Vpu-defective (Udel) NL4-3 HIV-1 pseudotyped with VSV-G.
LC3C depletion was verified by qRT-PCR (Figure S4A) and
BST2 depletion by western blot (Figure 3A). As previously
shown, the release of Vpu-defective HIV-1 was rescued in cells
depleted for BST2 compared to the control cells (Figures 3A,
lower panel, compare lane 9 versus lane 7, 3B, and S4B), consis-
tent with a restriction of Vpu-defective virus release by BST2.
Interestingly, LC3C depletion did not affect the release of WT
HIV-1 in BST2-depleted cells (Figures 3A and 3B). Similarly,Cell Reports 17, 2221–2233, November 22, 2016 2223
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Figure 2. LC3C Expression Is Required for Vpu-Mediated Enhancement of HIV-1 Release
(A) HeLa cells transfectedwith indicated siRNAwere infectedwith a VSV-G pseudotypedWTNL4-3 HIV-1 (MOI = 0.5). HIV-1-cell-associated CAp24 and released
CAp24 were measured by ELISA. HIV-1 release was calculated as the ratio between released CAp24 and total CAp24. Results were normalized to control cells,
which were set as 100%. Error bars represent SEM calculated on three independent experiments done in triplicate. ***p < 0.001.
(B). Western blot analysis of HIV-1 Gag and CAp24 products in infected siRNA-treated cells (upper panels) and pelleted virus (lower panel). Actin is the loading
control. Equal volumes of the viral samples were loaded. This western blot is representative of three independent experiments.
(legend continued on next page)
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release of Vpu-defective NL4-3 HIV-1 was no longer affected by
LC3C silencing in cells devoid of BST2 (Figures 3A and 3B,
compare lanes 9 and 10).
To further characterize the impact of LC3C on HIV-1 release,
we analyzed HIV-1 production in HEK293T cells, which do not
normally express BST2. Whereas the level of RNAi-mediated
LC3C knockdown was similar in HEK293T and HeLa cells (>
95%; Figure S4C), we did not observe any effect on HIV-1
release in HEK293T cells treated with LC3C siRNA (Figure S4D).
Similarly to what was observed in HEK293T cells depleted for
ATG5 or beclin 1 (Figure S1), the reduced amount of CAp24 in
pelleted virions was linked with a decrease in the amount of
cell-associated CAp24 in LC3C-silenced HEK293T cells (Fig-
ure S4E), suggesting a reduced permissiveness of siRNA-
treated HEK293T cells to HIV-1 infection or the requirement of
LC3C for other steps of the virus replication cycle.
Altogether, these data show that the effects observed after
LC3C silencing on HIV-1 release in restrictive cells depend on
BST2 expression and that LC3C may participate in Vpu activity
in counteracting BST2-mediated restriction of virus release.
Vpu Binds Specifically to LC3C
ATG8/LC3 proteins are critical factors for targeting cargos to
the autophagosomal membranes during selective autophagy
through the recognition of autophagy receptor-binding cargos
(Rogov et al., 2014). We postulated that Vpu could act as a re-
ceptor to favor the recruitment of cargos to LC3-positive mem-
branes by interacting with human ATG8 orthologs. HA-tagged
ATG8 orthologs were overexpressed together with GFP or
Vpu-GFP in HEK293T cells, and immunoprecipitations were per-
formed using an anti-GFP antibody. A specific interaction was
detected between Vpu-GFP and HA-LC3C, whereas no interac-
tion was observed between other human ATG8 orthologs and
Vpu-GFP (Figure 4A). Moreover, using purified recombinant pro-
teins, we found a direct interaction between His-tagged LC3C
and the purified cytoplasmic domain of Vpu fused to GST
(GST-VpuC) (Figure 4B). By contrast, no interaction between
Vpu-GFP and HA-tagged ATG5 was detected (Figure 4C, lane
4 versus lane 3).
We then analyzed the co-distribution of HA-LC3C with Vpu-
GFP using confocal microscopy. Vpu-GFP partially colocalized
with HA-tagged LC3C in HeLa cells (Figure S4F, lower panel),
but also with HA-tagged LC3A and LC3B (Figure S4F, upper
panels). Because no antibody directed against endogenous
LC3C works well in immunofluorescence, we next explored the(C) Cell-associated CAp24 and released CAp24 were measured by ELISA for siRN
bars represent SEM calculated on three independent experiments done in duplic
(D and E) Parental or knockout HeLa cells lacking LC3C (LC3C/ CRISPR 96#21
(MOI = 0.5). Cell-associated CAp24 and released CAp24 were measured by ELISA
were set as 100% (D). HIV-1 release was calculated as the ratio between releas
independent experiments done in simplicate. ***p < 0.001; **p < 0.01; *p < 0.05.
(F) Western blot analysis of HIV-1 Gag and CAp24 products in HIV-1 proviral DNA-
This western blot is representative of three independent experiments.
(G) Cryosections of HeLa cells treated with siControl (a) or siLC3C (b–d) and infec
CAp24 (a and b) or anti-MAp17 (c and d) and 10-nm protein A-gold. Images on the
of virus particles at the cell surface are indicated (black arrows in [a]). (b–d) Virus
appear to have a single membrane (white arrows in the right panels). MV, cell sur
panels, 200 nm.distribution of endogenous BST2 and ectopically expressed
Vpu-GFP with endogenous LC3B, a well-known marker of LC3
compartments found with Vpu-GFP on LC3+ structure (Fig-
ure S4F). Under physiological conditions, BST2 localized both
at the cell surface and in punctate structures in the cytoplasm
of HeLa cells, as previously described (Janvier et al., 2011);
Vpu displayed a perinuclear distribution and was also present
in some vesicles distributed throughout the cytoplasm (Fig-
ure 4D). Interestingly, some puncta labeled with endogenous
LC3Bwere co-labeled with Vpu-GFP andBST2 (Figure 4D, lower
enlarged panels). Altogether, these data reveal that Vpu interacts
specifically and directly with LC3C and is present with BST2 in
compartments containing human LC3 orthologs.
Vpu-LC3C Interaction Depends on the Integrity of the
Vpu L63VEM66 Sequence
Interaction with ATG8 family members is generally mediated by a
LIR motif whose consensus amino acid sequence is (W/F/Y)XX
(L/I/V) or by a non-canonical LIR motif, such as the CLIR motif
(LC3C-interacting region), corresponding to a succession of
hydrophobic residues preceded by acidic amino acids (Rogov
et al., 2014). We first investigated the contribution of the ‘‘dileu-
cine’’-like motif E59VSAL63V64 and the two serine residues of
the DS52GNES56 motif located in the cytoplasmic tail of Vpu to
the Vpu-LC3C interaction (Figure S5A). Immunoprecipitation of
WT or mutated Vpu-GFP showed that mutation of residues E59,
L63, and V64 to alanine (Vpu ELV-GFP) impaired the interaction
between Vpu and LC3C (Figure S5B, compare lanes 4 and 8).
By contrast, substitution of S52 and S56 residues to alanine did
not alter Vpu-LC3C interaction (Vpu 2/6-GFP, lane 6). These
data indicate that the integrity of E59XXXL63V64 motif is required
for efficientVpubinding toLC3C.Wenext performedanAla scan-
ningmutagenesis along the helix 2 of Vpu (Figure 5A).Whereas all
Vpu-GFPmutants werewell expressed, Vpu-GFP-bearingmuta-
tion on residues 58–60, 59–61, and 65–67 (Figure 5B, lanes 3, 4,
and 10) displayed a smaller apparent molecular weight, as
previously observed (Kueck and Neil, 2012). Mutagenesis of
amino acids 63–68 (lanes 6–11) altered Vpu-GFP binding to
HA-LC3C. Interestingly, simultaneous mutations on residues
L63VEM66 severely affected the binding of LC3C on Vpu in cellulo
and in vitro (Figures 5C, lane 5, and S5C), indicating that the
LC3C-binding site on Vpu includes amino acids L63VEM66.
Vpu selectively interacts with LC3C and not with other LC3 or-
thologs, suggesting that it does not bind to the LIR-binding
pocket conserved in all ATG8 orthologs (Noda et al., 2008). WeA-treated cells and normalized to control cells, which were set as 100%. Error
ate. **p < 0.01.
2 or CRISPR 97#9 clones) were transfected with WT NL4-3 HIV-1 proviral DNA
for LC3C/ HeLa cells and normalized to control cells (parental HeLa), which
ed CAp24 and total CAp24 (E). Error bars represent SEM calculated on three
transfected LC3C/HeLa cells and pelleted virus. Actin is the loading control.
ted with VSV-G pseudotyped WT NL4.3 HIV-1 labeled with antibodies against
right are enlargements of the regions indicated in the left-hand panels. Clusters
accumulations in intracellular vesicles in siLC3C cells. Note that the vesicles
face microvilli; N, nucleus. Scale bars for left panels, 1 mm. Scale bars for right
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Figure 3. Implication of LC3C in HIV-1 Release Requires BST2
Expression
HeLa cells were transfected with indicated siRNA and then infected with VSV-
G pseudotyped WT NL4-3 HIV-1 at MOI = 0.5.
(A) Western blot analysis of infected siRNA-treated cells. Tubulin is the loading
control. Equal volumes of the viral samples were loaded to visualize the rescue
of virus release in LC3C/BST2-depleted cells. This western blot is represen-
tative of three independent experiments.
(B) HIV-1 cell-associated CAp24 and CAp24 released into the supernatant of
the infected cells were measured by ELISA for LC3C and/or BST2-depleted
cells. HIV-1 release was calculated as the ratio between released CAp24 and
total CAp24. Results were normalized to those obtained for the control cells,
set as 100%. Error bars represent SEM calculated on three independent ex-
periments done in triplicate. ***p < 0.001.
2226 Cell Reports 17, 2221–2233, November 22, 2016thus tested binding of Vpu with LC3C mutated on residues K32/
F33/L64/F69 (referred to as LC3C Mut) specifically involved in
the binding of LC3C to the NDP52 CLIR motif (von Muhlinen
et al., 2012) (Figures S5D and S5E). These mutations decreased
NDP52 binding to LC3C and led to a better interaction with p62,
as previously reported (von Muhlinen et al., 2012), but did not
alter Vpu interaction with LC3C (Figures S5D and S5E). Alto-
gether, this suggests that Vpu-LC3C interaction does not involve
the same residues on LC3C as those of the NDP52 CLIR-binding
site.
We then examined the effect of LC3C depletion on the release
of WT or Vpu L63VEM66-mutated HIV-1 (HIV-1 Vpu L63VEM66) vi-
ruses in HeLa cells. In siControl cells, HIV-1 Vpu L63VEM66
viruses showed a reduced release in HeLa cells (30%
decrease) compared to the WT HIV-1, as observed by ELISA
quantification and western blot analysis (Figures 5D–5F). LC3C
silencing efficiently diminished HIV-1 WT release compared to
the control cells (25%), but did not further impact the release
of L63VEM66 mutated virus (Figures 5D–5F), supporting the
notion that LC3C may contribute to the ability of Vpu to coun-
teract BST2-mediated restriction of virus release through its
interaction with the Vpu L63VEM66 motif.
To validate that Vpu-LC3C interaction favors virus propagation
in a BST2-dependent manner, we evaluated, in LC3C-depleted
cells, the release of HIV Vpu mutant unable to physically interact
with BST2, but which retained the ability to interact with
LC3C.Mutated Vpu on residues A14 andW22 has been previously
described to lose its binding for BST2 (Vigan and Neil, 2010), and
mutation of these residues did not affect Vpu-LC3C interaction
(Figure 5C, lane 7). As shown in Figures 5D–5F, release of HIV
mutant A14W22 was low and not further affected in absence of
LC3C compared to theWT virus. Lastly, we analyzed the release
of thesemutated viruses inHEK293Tcells in the absence or pres-
ence of LC3C. Mutations on Vpu L63VEM66 or A14W22 residues
did not affect HIV release in BST2-deficient cells and LC3C
extinction had no effect on the release of these mutated viruses
(Figures S6A–S6C), suggesting that the effect of LC3C on HIV
release is dependent of BST2 expression and restriction.
LC3C Is Involved in Vpu-Mediated Removal of BST2 from
the Budding Site
Recent studies support the view that Vpu antagonizes BST2 by
removing it from viral budding sites at the plasmamembrane (Ja-
fari et al., 2014; McNatt et al., 2013). We thus used fluorescent in
cellulo proximity ligation assay technology (PLA-Duolink) be-
tween BST2 and HIV-1 Env present at the surface of infected
cells to determine the implication of LC3C in Vpu-mediated
removal of BST2 from the budding site. HeLa cells treated with
control or LC3C siRNA were infected with VSV-G-pseudotyped
WT or Vpu-deleted HIV-1 NL4.3 MA/YFP. The colocalization of
BST2 and Env at the cell surface, visualized as an individual
red fluorescent spot, was a rare event in control cells infected
with HIV-1 MA/YFP WT (green cells) (Figures 6A and 6B). Inter-
estingly, treatment with siRNA targeting LC3C increased the
number of duolink spots at the surface of cells infected with
HIV-1 MA/YFP WT, providing evidence for the close proximity
of BST2 to an Env-positive area at the surface of siLC3C-treated
cells (Figure 6B). A similar increase was also detected in cells
A B
C
c
G
S
T
G
S
T-
V
pu
H
is
 - 
LC
3C
6
c
αGST
Input 
His  -LC3C (μg)
0.5 0.25 0.12
GST-Vpu
GST-Vpuc
GST
GST
His  -LC3C 6 
His  -LC3C 
bound 
6 
6 
αLC3C
 1          2          3                4          5
Coomasie
blue
D BST2 LC3B Vpu-GFP
LC3B-BST2Vpu-BST2 Vpu-LC3B Merge
 1    2    3    4    5    6   7   8   9   10   11   12   
GFP
Vpu-GFP
H
A
-L
C
3A
H
A
-L
C
3B
H
A
-L
C
3C
H
A
-G
A
B
A
R
A
P
H
A
-G
A
B
A
R
A
P
L1
H
A
-G
A
B
A
R
A
P
L2
  +      -      +      -      +      -      +      -      +      -      +      -
   -      +      -      +      -      +      -      +      -      +      -      +
IP GFP
WB αHA
Lysate
WB αHA
IP GFP
WB αGFP
Lysate
WB αGFP
HA-LC3C
Vpu-GFP
Vpu-GFP
GFP
GFP
HA-ATG8
orthologs
25
17
25
17
46
25
25
46
HA-ATG5-ATG12
HA-ATG5
HA-LC3C
GFP
Vpu-GFP
HA-LC3C
Vpu-GFP
GFP
Lysate
WB αHA
Lysate
WB αGFP
IP GFP
WB αHA
IP GFP
WB αGFP
+        -        +        -HA-ATG5
HA-LC3C  -        +        -        +
1      2     3     4
GFP Vpu-GFP
62
17
62
17
46
25
46
25
Figure 4. LC3C Interacts with the HIV-1 Accessory Protein Vpu
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and visualized by confocal microscopy. Areas indicated by square are magnified in lower panels. Scale bars, 10 mm.infected with Vpu-defective HIV-1 MA/YFP (Udel), illustrating the
absence of Vpu-mediated removal of BST2 from the budding
site (Figures 6A and 6B).
This result was confirmed by the immunostaining of Env and
BST2 at the cell surface, followed by confocal microscopy anal-
ysis (Figure 6C). In cells infected with WT virus, BST2 labeling ofLC3-depleted cells was revealed in some areas at the plasma
membrane where Env staining and MA/YFP was detected,
whereas very little BST2-Env colocalization was observed at
the surface of control cells (Figure 6C, upper panel). As ex-
pected, a clear colocalization of BST2 with Env and MA/YFP at
the surface of Vpu-deleted HIV-1 infected cells (HIV-1 MA/YFPCell Reports 17, 2221–2233, November 22, 2016 2227
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Udel) was detected (Figure 6C, lower panel). Interestingly, in
cells infected with HIV-1 MA/YFP WT treated with control or
LC3C siRNA, the global level of BST2 stained at the cell surface
was reduced, presumably due to Vpu-mediated BST2 cell
surface downregulation (Figure 6C, upper panel). This was
corroborated by flow cytometry analysis in HeLa cells treated
with control or LC3C siRNA and transduced with lentivectors
encoding Vpu and ZsGreen proteins, showing that the cell
surface level of BST2 was still downregulated in the absence
of LC3C expression in cells expressing Vpu (Figures S6D and
S6E). Furthermore, a cycloheximide chase experiment also
showed that Vpu-mediated global BST2 downregulation was still
observed in LC3C-depleted cells (Figure S6F). In non-infected
cells and cells infected with Vpu-deleted virus, the turnover of
BST2 in LC3C-depleted cells is similar to that observed in control
cells, despite an increased level of BST2 detected in LC3C-
depleted cells infected with Vpu-deleted HIV-1. Altogether,
these experiments show that LC3C depletion does not modify
Vpu-mediated downregulation of BST2.
Lastly, we observed in LC3C-depleted cells infected with WT
HIV-1 the accumulation at the cell periphery of large and intense
MA/YFP puncta labeled with anti-Env compared to the small
puncta detected at or near the plasma membrane of control in-
fected cells (Figure 6C, upper panel), suggesting that LC3C
silencing induces the accumulation of viruses at the cell surface.
These data indicate that a fraction of BST2 remains in Env and
MA positive patches at the cell surface upon depletion of
LC3C, even in the presence of Vpu and despite an efficient
Vpu-mediated downregulation of BST2.
DISCUSSION
Host restriction factors are an important facet of the innate im-
mune response controlling infection in a cell-intrinsic manner.
Among them, the restriction factor BST2 interferes with HIV-1
replication by tethering mature HIV particles to the cell surface.
HIV-1 has developed a viral countermeasure, the small trans-
membrane protein Vpu, which removes BST2 molecules from
the budding site, and thus permits efficient dissemination of
newly formed virions. However, the mechanism by which Vpu
counteracts BST2 restriction is still not well understood. Here,
we propose that a non-canonical autophagic pathway, reminis-
cent of the LAP process involving a subset of ATG proteins, par-
ticipates in Vpu antagonism of BST2 restriction. During LAP, LC3
autophagic proteins associate with the single membrane of
the phagosome in an ATG5- and beclin 1-dependent manner,Figure 5. Binding of LC3C to Vpu Depends on the Integrity of L63VEM6
(A) Schematic representation of alanine mutagenesis in the second alpha helix o
(B and C) HEK293T cells were transfected with HA-tagged LC3C or LC3B and
proteins were immunoprecipitated with rabbit anti-GFP antibodies. Immunopreci
antibodies. Input was 4% of the immunoprecipitated material.
(D–F) HeLa cells were transfected with control siRNA (siControl) or siRNA targe
L63VEM66 or A14W22 mutated NL4-3 HIV-1. HIV-1 release was calculated as the ra
and released CAp24 were measured by ELISA quantification (E). Results were nor
bars represent SEM calculated on three independent experiments done in triplic
products in infected siRNA-treated cells (upper panels) and pelleted virus (lower p
were loaded to visualize the virus release. This western blot is representative ofbut independent of the autophagy preinitiation complex ULK1/
ATG13/FIP200. LAP is an important innate immune response,
by which conjugation of LC3 to phagosomal membranes accel-
erates phagosome fusion with lysosomes to eliminate dead cells
(Martinez et al., 2011) or fungal pathogens (Martinez et al., 2015)
and kill bacteria (Sanjuan et al., 2007). The implication of the LAP
process in Vpu counteraction of BST2 restriction is supported by
(1) the selective implication of ATG5, beclin 1, and LC3C proteins
in Vpu-mediated enhancement of HIV-1 release (Figures 1 and
2), (2) the immunoelectron microscopy pictures showing the
virus sequestered into a single membrane compartment in the
producer cells in the absence of LC3C (Figure 2), (3) the localiza-
tion of BST2 and Vpu molecules in LC3-positive compartments
(Figure 4), and (4) the detection of a direct and specific interac-
tion between Vpu and LC3C (Figures 4 and 5).
Thus, our data support a model in which Vpu engages a LAP
process, implicating the concerted action of LC3C, ATG5, and
beclin 1 proteins to counteract BST2 restriction onHIV-1 release.
Through its interaction with the transmembrane domain of BST2,
Vpu may selectively recruit LC3C to the plasma membrane in
areas enriched in BST2 molecules. The tight attachment of
LC3C under the plasma membrane through its lipidation could
be promoted by the positioning of ATG5 to the site where
LC3C is recruited. Indeed, studies have shown that ATG5 could
be directly recruited, independently of theULK complex, to a sin-
gle membrane vacuole formed during entosis and determines
the lipidation and docking of LC3 on these vacuoles (Florey
et al., 2011). Then, this local enrichment of LC3C induced by
Vpu may accelerate the phagocytosis of BST2 molecules, teth-
ering or not tethering the virus, leading to the removal of BST2
present at the budding site. The engagement of LAP process
by Vpu would selectively concern BST2 molecules present
at the budding site. This hypothesis is supported by the fact
that (1) LC3C participated in Vpu-mediated removal of BST2
from the viral budding site (Figure 6), but not in Vpu-mediated
BST2 cell surface downregulation (Figures S6D–S6F) and that
(2) LC3C silencing provokes an accumulation of Env and Gag
cleavage products at the cell surface (Figure 6). Next, LC3C-
associated phagocytosis elicited by Vpu may favor the fusion
with lysosomes of phagosomes containing BST2 and viruses
and promote their degradation. Indeed, attachment of LC3 mol-
ecules to the single phagosomal membrane results in enhanced
acidification and pathogen destruction (Sanjuan et al., 2007).
The detection of sequestrated viruses in single-membrane
compartments in LC3C-knockdown-infected cells (Figure 2)
and the accumulation of viruses in single membrane-bound6 Sequence of Vpu
f HIV-1 NL4.3 Vpu.
either GFP, Vpu-GFP, or Vpu-GFP mutated, as described in (A). GFP-tagged
pitated proteins were detected by western blotting using anti-HA and anti-GFP
ting LC3C (siLC3C), and then infected with VSV-G pseudotyped WT or Vpu
tio between released CAp24 and total CAp24 (D). HIV-1 cell-associated CAp24
malized to control cells infected with HIV-1 WT, which were set as 100%. Error
ate. ***p < 0.001; **p < 0.01. Western blot analysis of HIV-1 Gag and CAp24
anel) (D and E). Actin is the loading control. Equal volumes of the viral samples
three independent experiments (F).
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Figure 6. LC3C Is Required for Vpu to Remove BST2 from the Budding Site
(A) PLA-Duolink experiments highlighting the proximity between BST2 and HIV-1 Env proteins at the cell surface of HeLa cells infected (green cells) with VSV-G
pseudotyped wild-type (HIV-1 MA/YFP WT) and Vpu-deleted (HIV-1 MA/YFP Udel) YFP-tagged NL4.3 HIV-1 treated with indicated siRNA. PLA-Duolink ex-
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probes is visualized as an individual fluorescent spot (red) and quantified on microscopy images. Scale bars, 10 mm.
(B) Histogram shows the number of red spots counted per cell obtained from two independent experiments. Error bars represent SEM calculated on two
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compartments in cells infected with HIV-1 that do not express
Vpu support this notion (Neil et al., 2007). Therefore, in the
absence of LC3C or Vpu, the phagocytosis and the fusion of
the phagosomewith lysosomesmight be slowed down, resulting
in visualization of limited steps accelerated by Vpu activity on
LAP, i.e., the phagocytosis of BST2 molecules and virus from
the cell surface and the destruction of sequestered material.
Interestingly, we observe that LC3C silencing partially affects
Vpu activity on HIV-1 release and does not modify Vpu-mediated
BST2 downregulation (global cellular level and cell surface
expression) (Figures 3A, 6C, and S6D–S6F). This supports the
view, previously stated in the literature, that Vpu activity on
BST2 expression could be dispensable for Vpu-mediated
enhancement of HIV release (Miyagi et al., 2009; Tervo et al.,
2011). Moreover, our data documented an additional way for
Vpu to relieve BST2 restriction through engaging the LAP pro-
cess, in addition to its previously described activity on BST2
expression and trafficking to and from the cell surface (Dube´
et al., 2010; Neil et al., 2008; Van Damme et al., 2008). Vpu func-
tion on BST2 expression is related to Vpu capacity to enhance
BST2 ubiquitination through the recruitment of bTrCP (Goffinet
et al., 2009; Mangeat et al., 2009; Mitchell et al., 2009) and
thus to favor ESCRT-mediated sorting of BST2 for degradation
(Janvier et al., 2011). Vpu could thus, alternatively, either control
global level and cell surface expression of BST2 by accelerating
ESCRT-mediated degradation of BST2 through its interaction
with bTrCP or engage a LAP process at the budding sites via
its direct binding to LC3C (Jafari et al., 2014; McNatt et al.,
2013; Tervo et al., 2011).
The function of Vpu in the LAP process is somewhat reminis-
cent of the role of autophagy receptors that recognize cargos
(bacteria, aggregates, etc.) tagged with degradation signals
and the autophagosomal membrane through their LIR motif.
This triggers specific cargos’ degradation via selective auto-
phagy processes. Vpu could thus be considered as a LAP recep-
tor recruiting LC3C molecules onto phagosomes carrying BST2
molecules and accelerating the selective LAP of BST2molecules
at the budding site, whether or not they are docked to the viral
particles. Indeed, Vpu is found on LC3C-positive vesicles and
also on structures containing LC3A and LC3B (Figures 4 and
S4F). However, only LC3C and not other ATG8 family members
contributes to Vpu-mediated BST2 antagonism and thus effi-
cient HIV-1 release in restrictive cells (Figure 2), supporting the
notion that LC3C performs a function in Vpu-mediated BST2
counteraction that other ATG8 family members, despite their
presence on the same compartment, cannot execute. Moreover,
our data suggest that a specific interaction between LC3C and
Vpu is implicated in Vpu-mediated BST2 antagonism (Figures
4, 5, and S5). Vpu-LC3C interaction requires the integrity of the
L63VEM66 residues of Vpu, which are a part of the previously
described ‘‘dileucine’’-like motif E59VSAL63V64 (Figure 5B). The
L63VEM66 residues of Vpu are important for Vpu-mediated(C) HeLa cells transfected with either siRNA control or siRNA targeting LC3C
Vpu-deleted (HIV-1 MA/YFP Udel) YFP-tagged NL4.3 HIV-1. Cells were stain
antibodies and appropriate fluorophore-conjugated secondary antibodies, an
10 mm.optimal enhancement of HIV-1 release in restrictive cells (Fig-
ure 5) like the ‘‘dileucine’’-like motif (Jia et al., 2014; Kueck and
Neil, 2012) that is also required for Vpu to remove BST2 mole-
cules from the budding site (McNatt et al., 2013).
Interaction with ATG8 family members is generally mediated by
a LIR motif, whose consensus amino acid sequence is (W/F/Y)
XX(L/I/V) surrounded by at least one acidic residue. However,
the non-canonical CLIR motif, corresponding to a succession of
hydrophobic residues preceded by acidic amino acids, has
been recently described in the NDP52 xenophagy receptor and
allows the targeting of ubiquitinated bacteria to the phagophore
membrane via its binding to LC3C (von Muhlinen et al., 2012).
HIV-1 NL4-3 Vpu L63VEM66 sequence is not a consensus LIR
motif, but presents a stretch of hydrophobic residues located
downstream of the acidic amino acids (E55XE57XE59) (Figure 5A).
Vpu L63VEM66 sequence overlaps the ‘‘dileucine’’-like motif,
which was previously implicated in Vpu binding to the clathrin
adaptor complex 1 (AP1) and required for Vpu-induced BST2
cell surface downregulation and degradation (Kueck and Neil,
2012). This sequence could thus recognize, on one hand, the
AP1 clathrin adaptor to regulate BST2 trafficking through the en-
dosomal pathway and, on the other hand, LC3C to favor the
removing of BST2 present at the budding site and HIV release.
LC3C has been previously implicated in selective autophagy
directed against bacteria (von Muhlinen et al., 2012). Usurpation
of LC3C by a viral protein to counteract a restriction factor
through a LAP process has never been reported despite
numerous studies regarding the role of ATG proteins in viral
infection, notably on the HIV replication cycle (Dinkins et al.,
2010). Therefore, this study reveals an additional mode of action
of a viral protein to overcome an intrinsic viral defense process.
Future work will be required to explore in depth the role of the
LAP in the viral countermeasures deployed against BST2, a
general restriction factor of enveloped viruses.
EXPERIMENTAL PROCEDURES
For detailed protocols of cell culture, antibodies, siRNA, expression vectors,
CRISPR-Cas9 knockout, flow cytometry analysis, GST pull down, immunopre-
cipitations, HIV production assay, immuno-electron, and fluorescencemicros-
copies, see Supplemental Experimental Procedures.
Small Interfering RNA Transfection
Small interfering RNA transfections were performed with 5–30 nM siRNA using
Lipofectamine RNAiMAX (Life Technologies). See Supplemental Experimental
Procedures for details.
CRISPR-Cas9 Knockout
Expression plasmids for single guide RNA (sgRNA) targeting the LC3C gene
were transfected into HeLa cells, along with a plasmid expressing Cas9 fused
with GFP. The following target sequences were used: 50-GCTTGAAGGGTCT
GACGCTT-30 (LC3C, exon 1; guide 1) and 50-TGCTTGAAGGGTCTGACGCT-
30 (LC3C, exon 1; guide 2). See Supplemental Experimental Procedures for
details.were infected with VSV-G pseudotyped wild-type (HIV-1 MA/YFP WT) and
ed 48 hr post-infection at 4C with mouse anti-Env and rabbit anti-BST2
d then fixed with PFA and visualized by confocal microscopy. Scale bars,
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HIV-1 Production Assay
SiRNA-treated HeLa or HEK293T cells were infected 48 hr after siRNA
transfection with NL4-3 (WT or mutated) HIV-1 pseudotyped with VSV-G.
Supernatants and cell lysates were collected 48 hr after infection and
used for HIV-1 CAp24 quantification by ELISA. Viral particles released were
pelleted by ultracentrifugation. See Supplemental Experimental Procedures
for details.
Immunoprecipitations
Coimmunoprecipitations were performed 24 hr after transfection of 293T cells
by incubating indicated whole cell extracts for 3 hr with polyclonal rabbit anti-
GFP antibody coupled with Dynabeads protein G (Life Technologies). See
Supplemental Experimental Procedures for details.
Pull-Down Experiments
Pull-down experiments were performed by incubating 5 mg of purified LC3C
protein with 4 mg of GST beads or GST-Vpuc beads in interaction buffer for
3 hr at room temperature. See Supplemental Experimental Procedures for
details.
Fluorescence Microscopy
HeLa cells grown on coverslips were either fixed with methanol at 20C or
with 4% paraformaldehyde in PBS (PFA). For extracellular staining of BST2,
living cells were incubated for 1 hr at 4C with corresponding antibodies and
then fixed.
For PLA-Duolink assay, living cells were labeled as described above, fixed,
and labeled with PLA Probe Anti-Rabbit PLUS and PLA Probe Anti-Mouse
MINUS, as described by the manufacturer (Sigma Aldrich).
Microscope Spinning Disk DMI6000B Leica was used for confocal analysis.
Images were processed using ImageJ software. Quantitative colocalization
analysis was done with the JACoP tool (ImageJ software) using Pearson’s
correlation coefficient. For PLA-Duolink, the signal was quantified with the
Analyze particles tool (ImageJ software). See Supplemental Experimental
Procedures for details.
Statistical Analysis
Statistical significance was analyzed by paired two-tailed Student’s t test and
the one-way Anova test, and expressed as a p value. Each experiment was
performed independently at least three times to ensure minimal robustness
of the statistical analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.10.045.
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